Literature DB >> 22697260

Fragment-based approaches in drug discovery and chemical biology.

Duncan E Scott1, Anthony G Coyne, Sean A Hudson, Chris Abell.   

Abstract

Fragment-based approaches to finding novel small molecules that bind to proteins are now firmly established in drug discovery and chemical biology. Initially developed primarily in a few centers in the biotech and pharma industry, this methodology has now been adopted widely in both the pharmaceutical industry and academia. After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes. Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, β-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase. The role of fragment-based approaches in an academic research environment is also examined with an emphasis on neglected diseases such as tuberculosis. The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697260     DOI: 10.1021/bi3005126

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  114 in total

1.  Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration.

Authors:  Frank E Kwarcinski; Michael E Steffey; Christel C Fox; Matthew B Soellner
Journal:  ACS Med Chem Lett       Date:  2015-07-13       Impact factor: 4.345

2.  Liganding Functional Tyrosine Sites on Proteins Using Sulfur-Triazole Exchange Chemistry.

Authors:  Jeffrey W Brulet; Adam L Borne; Kun Yuan; Adam H Libby; Ku-Lung Hsu
Journal:  J Am Chem Soc       Date:  2020-04-24       Impact factor: 15.419

3.  A three-stage biophysical screening cascade for fragment-based drug discovery.

Authors:  Ellene H Mashalidis; Paweł Śledź; Steffen Lang; Chris Abell
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

4.  Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol.

Authors:  Tian Zhu; Hyun Lee; Hao Lei; Christopher Jones; Kavankumar Patel; Michael E Johnson; Kirk E Hevener
Journal:  J Chem Inf Model       Date:  2013-03-14       Impact factor: 4.956

5.  Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.

Authors:  Katherine Deigan Warner; Adrian R Ferré-D'Amaré
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

Review 6.  Genetic Approaches to Facilitate Antibacterial Drug Development.

Authors:  Dirk Schnappinger
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-13       Impact factor: 6.915

7.  An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells.

Authors:  Ekaterina V Vinogradova; Xiaoyu Zhang; David Remillard; Daniel C Lazar; Radu M Suciu; Yujia Wang; Giulia Bianco; Yu Yamashita; Vincent M Crowley; Michael A Schafroth; Minoru Yokoyama; David B Konrad; Kenneth M Lum; Gabriel M Simon; Esther K Kemper; Michael R Lazear; Sifei Yin; Megan M Blewett; Melissa M Dix; Nhan Nguyen; Maxim N Shokhirev; Emily N Chin; Luke L Lairson; Bruno Melillo; Stuart L Schreiber; Stefano Forli; John R Teijaro; Benjamin F Cravatt
Journal:  Cell       Date:  2020-07-29       Impact factor: 41.582

8.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

Review 9.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

10.  Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

Authors:  Cy V Credille; Benjamin L Dick; Christine N Morrison; Ryjul W Stokes; Rebecca N Adamek; Nicholas C Wu; Ian A Wilson; Seth M Cohen
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.